Iterum Therapeutics (Nasdaq:ITRM) - Hisse Senedi Fiyatı, Haberler ve Analizler

ITRM Stoklara Genel Bakış

ITRM temel anali̇z
Kar Tanesi Skoru
Değerleme	0/6
Gelecekteki Büyüme	2/6
Geçmiş Performans	0/6
Finansal Sağlık	0/6
Temettüler	0/6

Ödüller

Gelirin yılda 74.82% oranında artması öngörülüyor

Kazançlar son 5 yılda yılda 26% oranında arttı

Risk Analizi

Son 3 ayda hisse senedi fiyatı oldukça dalgalıydı

Geliri 1 milyon ABD dolarından az ( $0 )

Hissedarlar geçen yıl önemli ölçüde sulandırıldı

Negatif hissedar öz sermayesi

+ 3 daha fazla risk

Iterum Therapeutics plc Rakipler

Earth Science Tech

OTCPK:ETST

US$39.6m

Anebulo Pharmaceuticals

NasdaqCM:ANEB

US$36.3m

VYNE Therapeutics

NasdaqCM:VYNE

US$42.6m

Lexaria Bioscience

NasdaqCM:LEXX

US$37.2m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Iterum Therapeutics
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$2.03
52 Haftanın En Yüksek Seviyesi	US$2.39
52 Haftanın En Düşük Seviyesi	US$0.81
Beta	2.25
11 Aylık Değişim	41.96%
3 Aylık Değişim	79.65%
1 Yıllık Değişim	-2.87%
33 Yıllık Değişim	-70.44%
5 Yıllık Değişim	-95.08%
Halka arzdan bu yana değişim	-98.95%

Son Haberler & Güncellemeler

Recent updates

Despite Risks Around Regulatory Approval, Iterum Therapeutics Rates A Speculative Buy

Jul 05

It's Unlikely That The CEO Of Iterum Therapeutics plc (NASDAQ:ITRM) Will See A Huge Pay Rise This Year

Jun 11

Is Iterum Therapeutics (NASDAQ:ITRM) Using Debt Sensibly?

May 20

Have Insiders Been Selling Iterum Therapeutics plc (NASDAQ:ITRM) Shares?

Feb 04

This Insider Has Just Sold Shares In Iterum Therapeutics plc (NASDAQ:ITRM)

Feb 04

Iterum Therapeutics shares slide 13% on raising $10M

Feb 03

Iterum Therapeutics rises 39% on RA Capital stake disclosure

Dec 03

Iterum Therapeutics files US application for sulopenem in urinary tract infections

Nov 30

Iterum Therapeutics EPS beats by $0.45

Nov 16

Hissedar Getirileri

	ITRM	US Pharmaceuticals	US Pazar
7D	24.5%	4.2%	2.0%
1Y	-2.9%	13.7%	32.4%

Getiri vs. Endüstri: ITRM geçen yıl % 13.7 oranında getiri sağlayan US Pharmaceuticals sektörünün gerisinde kaldı.

Getiri vs Piyasa: ITRM geçen yıl % 32.4 oranında getiri sağlayan US Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is ITRM's price volatile compared to industry and market?
ITRM volatility
ITRM Average Weekly Movement	21.7%
Pharmaceuticals Industry Average Movement	9.7%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.9%
10% least volatile stocks in US Market	3.1%

İstikrarlı Hisse Senedi Fiyatı: ITRM hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: ITRM 'nin haftalık oynaklığı geçtiğimiz yıl boyunca 15% dan 22% a yükseldi.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2015	14	Corey Fishman	www.iterumtx.com

Klinik aşamada bir ilaç şirketi olan Iterum Therapeutics plc, İrlanda, Bermuda ve Amerika Birleşik Devletleri'nde anti-enfektiflerin geliştirilmesi ve ticarileştirilmesi ile ilgilenmektedir. Komplike olmayan idrar yolu enfeksiyonları, komplike idrar yolu enfeksiyonları ve komplike intra-abdominal enfeksiyonların tedavisi için Faz III klinik çalışmalarda olan oral ve intravenöz formülasyonlara sahip yeni bir anti-enfektif bileşik olan sulopenem geliştirmektedir. Şirket 2015 yılında kurulmuştur ve merkezi İrlanda'nın Dublin kentindedir.

Iterum Therapeutics plc Temel Bilgiler Özeti

Iterum Therapeutics'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
ITRM temel i̇stati̇sti̇kler
Piyasa değeri	US$56.41m
Kazançlar(TTM)	-US$30.55m
Gelir(TTM)	n/a

0.0x

P/S Oranı

-1.8x

F/K Oranı

ITRM aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
ITRM gelir tablosu (TTM)
Gelir	US$0
Gelir Maliyeti	US$0
Brüt Kâr	US$0
Diğer Giderler	US$30.55m
Kazançlar	-US$30.55m

Son Raporlanan Kazançlar

Sep 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-1.11
Brüt Marj	0.00%
Net Kâr Marjı	0.00%
Borç/Özkaynak Oranı	-195.0%

ITRM uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

ITRM Stoklara Genel Bakış

Ödüller

Risk Analizi

Iterum Therapeutics plc Rakipler

OTCPK:ETST

US$39.6m

NasdaqCM:ANEB

US$36.3m

NasdaqCM:VYNE

US$42.6m

NasdaqCM:LEXX

US$37.2m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Iterum Therapeutics Regains Full Nasdaq Compliance with Listing Rule 5550(b)

Iterum Therapeutics plc to Report Q3, 2024 Results on Nov 14, 2024

Iterum Therapeutics plc Receives U.S. FDA Approval of ORLYNVAH (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections

Iterum Therapeutics Receives Formal Notice from Nasdaq Panel to Consider its Appeal at an Oral Hearing on November 21, 2024

Iterum Therapeutics Receives Delisting Determination Letter from Nasdaq Regarding its Failure to Meet the Terms of the Extension to Comply with the Minimum Stockholders’ Equity Requirement

New major risk - Shareholder dilution

Recent updates

Iterum Therapeutics Regains Full Nasdaq Compliance with Listing Rule 5550(b)

Iterum Therapeutics plc to Report Q3, 2024 Results on Nov 14, 2024

Iterum Therapeutics plc Receives U.S. FDA Approval of ORLYNVAH (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections

Iterum Therapeutics Receives Formal Notice from Nasdaq Panel to Consider its Appeal at an Oral Hearing on November 21, 2024

Iterum Therapeutics Receives Delisting Determination Letter from Nasdaq Regarding its Failure to Meet the Terms of the Extension to Comply with the Minimum Stockholders’ Equity Requirement

New major risk - Shareholder dilution

Forecast to breakeven in 2026

Iterum Therapeutics plc to Report Q2, 2024 Results on Aug 14, 2024

New major risk - Shareholder dilution

Iterum Therapeutics plc Broadens Patent Estate for Oral Sulopenem

New major risk - Financial position

Iterum Therapeutics plc Receives FDA Acceptance of Resubmission of NDA for Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections

Iterum Therapeutics plc Announces Executive Changes

Iterum Therapeutics plc to Report Q1, 2024 Results on May 13, 2024

Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem

Iterum Therapeutics plc, Annual General Meeting, Jun 19, 2024

Insufficient new directors

Iterum Therapeutics plc to Report Q4, 2023 Results on Mar 28, 2024

Iterum Therapeutics plc Announces Positive Topline Results from Its Phase 3 Reassure Clinical Trial of Oral Sulopenem in Un Complicated Urinary Tract Infections

New major risk - Financial position

Iterum Therapeutics plc Announces the Resignation of Mark Chin as Director, Effective December 31, 2023

New major risk - Revenue and earnings growth

Iterum Therapeutics plc to Report Q3, 2023 Results on Nov 14, 2023

New minor risk - Share price stability

Iterum Therapeutics plc Announces Completion of Enrollment in its REASSURE Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections

Iterum Therapeutics Receives a Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Iterum Therapeutics plc to Report Q2, 2023 Results on Aug 11, 2023

Iterum Therapeutics plc, Annual General Meeting, May 03, 2023

Iterum Therapeutics plc to Report Q3, 2022 Results on Nov 10, 2022

Iterum Announces First Patient Dosed in Reassure, A Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections

Iterum Therapeutics plc Announces Issuance of Allowance for A U.S. Patent Covering Oral Sulopenem

Iterum Therapeutics Regains Compliance with Nasdaq Bid Price Rule

Does Iterum Therapeutics (NASDAQ:ITRM) Have A Healthy Balance Sheet?

Iterum Therapeutics Non-GAAP EPS of -$0.03 beats by $0.03

Iterum Therapeutics plc Announces Special Protocol Assessment Agreement with the FDA

Iterum jumps 64% as FDA agrees to Phase 3 trial for UTI candidate

Does Iterum Therapeutics (NASDAQ:ITRM) Have A Healthy Balance Sheet?

Iterum Therapeutics plc, Annual General Meeting, Jun 15, 2022

Iterum Therapeutics plc to Report Q4, 2021 Results on Mar 28, 2022

Does Iterum Therapeutics (NASDAQ:ITRM) Have A Healthy Balance Sheet?

Iterum Therapeutics Provides Update from FDA Type A Meeting Regarding Oral Sulopenem

Is Iterum Therapeutics (NASDAQ:ITRM) A Risky Investment?

Bernstein Liebhard Reminds Investors of the Deadline to File Lead Plaintiff Motion in Securities Class Action Lawsuit Filed Against Iterum Therapeutics plc

Pomerantz Law Firm Announces the Filing of Class Action against Iterum Therapeutics plc and Certain Officers

Despite Risks Around Regulatory Approval, Iterum Therapeutics Rates A Speculative Buy

Iterum Therapeutics plc Receives Letter from the U.S. Food and Drug Administration as Part of Their Ongoing Review of the New Drug Application for sulopenem etzadroxil/probenecid

Independent Director Mohammed Shahzad Malik has left the company

It's Unlikely That The CEO Of Iterum Therapeutics plc (NASDAQ:ITRM) Will See A Huge Pay Rise This Year

Consensus forecasts updated

Iterum Therapeutics plc Provides Update on NDA Review

Is Iterum Therapeutics (NASDAQ:ITRM) Using Debt Sensibly?

Price target increased to US$2.00

Consensus revenue estimates increase to US$2.86m

Independent Director has left the company

Iterum Therapeutics Appoints Beth P. Hecht to Board of Directors

Iterum Therapeutics plc to Report Q4, 2020 Results on Mar 12, 2021

New 90-day high: US$2.27

Have Insiders Been Selling Iterum Therapeutics plc (NASDAQ:ITRM) Shares?

This Insider Has Just Sold Shares In Iterum Therapeutics plc (NASDAQ:ITRM)